File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Perspective and challenges of mesenchymal stem cells for cardiovascular regeneration

TitlePerspective and challenges of mesenchymal stem cells for cardiovascular regeneration
Authors
Issue Date2013
Citation
Expert Review of Cardiovascular Therapy, 2013, v. 11, p. 505-517 How to Cite?
AbstractMesenchymal stem cells (MSCs) exhibit multipotent differentiation potential and can be derived from embryonic, neonatal and adult differentiation stage III tissue sources. While increasing preclinical studies and clinical trials have indicated that MSC-based therapy is a promising strategy for cardiovascular regeneration, there are major challenges to overcome before this stem-cell technology can be widely applied in clinical settings. In this review, the following important issues will be addressed. First, optimal sources of MSC derivation suitable for myocardial repair are not determined. Second, assessments for preclinical and clinical studies of MSCs require more scientific data analysis. Third, mechanisms of MSC-based therapy for cardiovascular regeneration have not been fully understood yet. Finally, the potential benefit-risk ratio of MSC therapy needs to be evaluated systematically. Additionally, future development of MSC therapy will be discussed.
Persistent Identifierhttp://hdl.handle.net/10722/189255

 

DC FieldValueLanguage
dc.contributor.authorZHANG, Yen_US
dc.contributor.authorLIANG, Xen_US
dc.contributor.authorLian, Qen_US
dc.contributor.authorTse, HFen_US
dc.date.accessioned2013-09-17T14:30:59Z-
dc.date.available2013-09-17T14:30:59Z-
dc.date.issued2013en_US
dc.identifier.citationExpert Review of Cardiovascular Therapy, 2013, v. 11, p. 505-517en_US
dc.identifier.urihttp://hdl.handle.net/10722/189255-
dc.description.abstractMesenchymal stem cells (MSCs) exhibit multipotent differentiation potential and can be derived from embryonic, neonatal and adult differentiation stage III tissue sources. While increasing preclinical studies and clinical trials have indicated that MSC-based therapy is a promising strategy for cardiovascular regeneration, there are major challenges to overcome before this stem-cell technology can be widely applied in clinical settings. In this review, the following important issues will be addressed. First, optimal sources of MSC derivation suitable for myocardial repair are not determined. Second, assessments for preclinical and clinical studies of MSCs require more scientific data analysis. Third, mechanisms of MSC-based therapy for cardiovascular regeneration have not been fully understood yet. Finally, the potential benefit-risk ratio of MSC therapy needs to be evaluated systematically. Additionally, future development of MSC therapy will be discussed.-
dc.languageengen_US
dc.relation.ispartofExpert Review of Cardiovascular Therapyen_US
dc.titlePerspective and challenges of mesenchymal stem cells for cardiovascular regenerationen_US
dc.typeArticleen_US
dc.identifier.emailLian, Q: qzlian@hkucc.hku.hken_US
dc.identifier.emailTse, HF: hftse@hkucc.hku.hken_US
dc.identifier.authorityLian, Q=rp00267en_US
dc.identifier.authorityTse, HF=rp00428en_US
dc.identifier.doi10.1586/erc.13.5-
dc.identifier.pmid23570363-
dc.identifier.hkuros223118en_US
dc.identifier.hkuros225193-
dc.identifier.hkuros241268-
dc.identifier.volume11en_US
dc.identifier.spage505en_US
dc.identifier.epage517en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats